Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study.

Clinical rheumatology - 1 Feb 2014

Szalay Balázs, Vásárhelyi Barna, Cseh Aron, Tulassay Tivadar, Deák Magdolna, Kovács László, Balog Attila

Abstract excerpt

Rheumatoid arthritis (RA) is an autoimmune disease characterized by abnormal prevalence of Th1, Th2, Th17, and regulatory (Treg) subsets. Some data suggest that these subsets are influenced by anti-RA agents. Follow-up studies monitoring T cell phenotype in response to therapy are limited. We investigated the alteration of CD4+ T cell subset distribution after the initiation of disease-modifying antirheumatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biological Products

Share to Etanercept

Share to Infliximab

Share to Lymphocyte Subsets

Share to Receptors, Tumor Necrosis Factor

Share to Th17 Cells

Source

Identifiers

PMID: 23934385
DOI: 10.1007/s10067-013-2352-x

Genes

ADA
TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study.PMID 23934385Read ↗

The Impact of Anti-TNF Therapy on CD4+ and CD8+ Cell Subsets in Ankylosing Spondylitis.Semantic proximity Read ↗

Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept.Semantic proximity Read ↗

B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis.Semantic proximity Read ↗

Peripheral blood cellular dynamics of Rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugsSemantic proximity Read ↗

TCR repertoire analysis reveals effector memory T cells differentiation into Th17 cells in rheumatoid arthritisSemantic proximity Read ↗

Effects of Biological Therapies on Molecular Features of Rheumatoid ArthritisSemantic proximity Read ↗

Role of Th17 cells in human autoimmune arthritis.Semantic proximity Read ↗

Defining immune cell phenotypes that distinguish treatment responders and non-responders in RA.Semantic proximity Read ↗

Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to Disease Activity Score-28Semantic proximity Read ↗

Clinical Impact of Interferon-γ in Anti-Citrullinated Protein Antibody-Positive Rheumatoid ArthritisSemantic proximity Read ↗

Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis.Semantic proximity Read ↗

T cells: pathogenic cells and therapeutic targets in rheumatoid arthritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.